Post-marketing surveillance of 10,392 herpes zoster vaccines doses in Australia
Open Access
- 25 April 2024
- Vol. 42 (13) , 3166-3171
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Active Postlicensure Safety Surveillance for Recombinant Zoster Vaccine Using Electronic Health Record DataAmerican Journal of Epidemiology, 2022
- Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022MMWR. Morbidity and Mortality Weekly Report, 2022
- Herpes zoster: A Review of Clinical Manifestations and ManagementViruses, 2022
- Risk of Guillain-Barré Syndrome Following Recombinant Zoster Vaccine in Medicare BeneficiariesJAMA Internal Medicine, 2021
- Herpes Zoster Vaccine Live and Risk of Stroke Among Medicare BeneficiariesStroke, 2021
- Review of the initial post-marketing safety surveillance for the recombinant zoster vaccineVaccine, 2020
- The comparative efficacy and safety of herpes zoster vaccines: A network meta-analysisVaccine, 2019
- Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) — United States, October 2017–June 2018MMWR. Morbidity and Mortality Weekly Report, 2019
- Prevention of herpes zoster and its complications: from the clinic to the real-life experience with the vaccineJournal of Medical Microbiology, 2016
- Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)Vaccine, 2015